Albertas U.
- Country
- Lithuania
- Department
- None
Research Overview
- Pharmacokinetics of Radium-223 Dichloride in Patients with Prostate Cancer Undergoing Radium-223 Treatment
- Evaluation of Teverelix DP, a GnRH Antagonist, in Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety for Advanced Prostate Cancer Patients
- Phase 3 Randomized Open-label Study of Opevesostat Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
Data & Insights
Has run more than one trial at 34 of 217 partner sites.
Specializations
Prostate Cancer Treatment
This investigator specializes in treating various stages of prostate cancer, with particular expertise in managing advanced prostate cancer and its metastatic forms.
- Hormone Therapy Management
- Metastatic Disease Treatment
- Castration-Resistant Cases
Their research encompasses both hormone-sensitive and castration-resistant disease states.
Novel Therapeutic Approaches
The investigator focuses on evaluating innovative treatments including GnRH antagonists and targeted radiation therapy for prostate cancer management.
- Androgen Deprivation Therapy
- Radiopharmaceutical Treatment
- Novel Hormonal Agents
Their work includes assessment of emerging therapeutic compounds and established treatment modalities.
Treatment Optimization
The investigator studies treatment sequencing and combination approaches in prostate cancer therapy.
- Comparative Treatment Studies
- Long-term Treatment Outcomes
- Therapy Response Assessment
Their research aims to optimize therapeutic strategies for different disease stages.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.